For sure! I think #1 is the primary reason for these other indications. It is a longer term play while we are only looking at the daily share price. Personally I like this approach as long as they are pursuing indications that are linked to CCR5 (which they are and even prioritizing them) and not just throwing trials around to see what sticks.

Maybe it is just me, but seems they have slowed down on the 8 pre-clinical cancers MOA (RP excluded). This may also be intentional to avoid a BO with our current share price. We've talked about it before, but seems our share price is too low for a BP to value all those cancer indications and BOD can't accept pennies on a dollar valuation either. Not trying to start a confrontational debate, but if this is the situation, is this right by the cancer patients? If pursuing cancer studies aggressively and getting large (but pennies on the dollar) BO offers is that right by the shareholders? Tough position to be in and if I was in the other boat I would probably vote different, but I vote for the shareholders as they have the 'Right to Try' and 'Expanded Access' available for those in need until our financing is firmed up to move cancer trials as fast as possible.